Preparation of Saxagliptin, a Novel DPP-IV Inhibitor
Citations Over TimeTop 19% of 2009 papers
Abstract
The commercial-scale synthesis of the DPP-IV inhibitor, saxagliptin (1), is described from the two unnatural amino acid derivatives 2 and 3. After the deprotection of 3, the core of 1 is formed by the amide coupling of amino acid 2 and methanoprolinamide 4. Subsequent dehydration of the primary amide and deprotection of the amine affords saxagliptin, 1. While acid salts of saxagliptin have proven to be stable in solution, synthesis of the desired free base monohydrate was challenging due to the thermodynamically favorable conversion of the free amine to the six-membered cyclic amidine 9. Significant process modifications were made late in development to enhance process robustness in preparation for the transition to commercial manufacturing. The impetus and rationale for those changes are explained herein.
Related Papers
- → The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial(2012)66 cited
- → Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus(2020)11 cited
- → Appraisal of Saxagliptin as Treatment of Type 2 Diabetes(2010)3 cited
- → ChemInform Abstract: Synthesis and Evaluation of Duocarmycin and CC‐1065 Analogues Containing Modifications in the Subunit Linking Amide.(1999)
- 2 型糖尿病患者における新規 DPP－4 阻害薬サキサグリプチンの有用性―国内で行われた臨床試験を中心に―(2013)